Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU Corrigendum in /10.3892/mmr.2018.9415 Retraction in /10.3892/mmr.2023.12974

Tang,Bo; Hu,Zhigao; Li,Yang; Yuan,Shengguang; Wang,Zhenran; Yu,Shuiping; He,Songqing

doi:10.3892/mmr.2015.4511

Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU Corrigendum in /10.3892/mmr.2018.9415

Retraction in: /10.3892/mmr.2023.12974

Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU

Corrigendum in: /10.3892/mmr.2018.9415 Retraction in /10.3892/mmr.2023.12974

Authors:
- Bo Tang
- Zhigao Hu
- Yang Li
- Shengguang Yuan
- Zhenran Wang
- Shuiping Yu
- Songqing He
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Guilin Medical University, Affiliated Hospital, Guilin, Guangxi 541001, P.R. China
Published online on: November 6, 2015 https://doi.org/10.3892/mmr.2015.4511
Pages: 59-66
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

δ opioid receptor (DOR) was the first opioid receptor of the G protein‑coupled receptor family to be cloned. Our previous studies demonstrated that DOR is involved in regulating the development and progression of human hepatocellular carcinoma (HCC), and is involved in the regulation of the processes of invasion and metastasis of HCC cells. However, whether DOR is involved in the development and progression of drug resistance in HCC has not been reported and requires further elucidation. The aim of the present study was to investigate the expression levels of DOR in the drug‑resistant HCC BEL‑7402/5‑fluorouracil (BEL/FU) cell line, and its effects on drug resistance, in order to preliminarily elucidate the effects of DOR in HCC drug resistance. The results of the present study demonstrated that DOR was expressed at high levels in the BEL/FU cells, and the expression levels were higher, compared with those in normal liver cells. When the expression of DOR was silenced, the proliferation of the drug‑resistant HCC cells were unaffected. However, when the cells were co‑treated with a therapeutic dose of 5‑FU, the proliferation rate of the BEL/FU cells was significantly inhibited, a large number of cells underwent apoptosis, cell cycle progression was arrested and changes in the expression levels of drug‑resistant proteins were observed. Overall, the expression of DOR was upregulated in the drug‑resistant HCC cells, and its functional status was closely associated with drug resistance in HCC. Therefore, DOR may become a recognized target molecule with important roles in the clinical treatment of drug‑resistant HCC.

View Figures

View References

1	Okuda K: Hepatocellular carcinoma. J Hepatol. 32(1 Suppl): 225–237. 2000. View Article : Google Scholar : PubMed/NCBI
2	Wörns MA and Galle PR: Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 42(Suppl 3): S302–S309. 2010. View Article : Google Scholar : PubMed/NCBI
3	Rampone B, Schiavone B, Martino A, Viviano C and Confuorto G: Current management strategy of hepatocellular carcinoma. World J Gastroenterol. 15:3210–3216. 2009. View Article : Google Scholar : PubMed/NCBI
4	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
5	Poupon R, Fartoux L and Rosmorduc O: Therapeutic advances in hepatocellular carcinoma. Bull Acad Natl Med. 192:23–32. 2008.In French.
6	Marin JJ, Romero MR and Briz O: Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr Med Chem. 17:709–740. 2010. View Article : Google Scholar : PubMed/NCBI
7	Li G, Chen X, Wang Q, Xu Z, Zhang W and Ye L: The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J Huazhong Univ Sci Technolog Med Sci. 27:173–175. 2007. View Article : Google Scholar : PubMed/NCBI
8	Chow EK, Fan LL, Chen X and Bishop JM: Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells. Hepatology. 56:1331–1341. 2012. View Article : Google Scholar : PubMed/NCBI
9	Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des. 12:273–286. 2006. View Article : Google Scholar : PubMed/NCBI
10	Zhai BJ, Shao ZY, Zhao CL, Hu K and Wu F: Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice. World J Gastroenterol. 12:6614–6619. 2006.PubMed/NCBI
11	Yan F, Wang XM, Pan C and Ma QM: Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells. World J Gastroenterol. 15:1443–1451. 2009. View Article : Google Scholar : PubMed/NCBI
12	Li B, Ye T, Zhao L, Li DH, Gou XH, Zhao LY, Han L, Chen L, Yan LN and Gong JP: Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int. 5:552–559. 2006.PubMed/NCBI
13	Warmann S, Göhring G, Teichmann B, Geerlings H, Pietsch T and Fuchs J: P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res. 23:4607–4611. 2003.
14	Tang B, Li Y, Yuan S, Tomlinson S and He S: Upregulation of the δ opioid receptor in liver cancer promotes liver cancer progression both in vitro and in vivo. Int J Oncol. 43:1281–1290. 2013.PubMed/NCBI
15	Zhang B, Zhang X, Tang B, Zheng P and Zhang Y: Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression. Breast Cancer Res Treat. 136:399–406. 2012. View Article : Google Scholar : PubMed/NCBI
16	Wang C, Lisanti MP and Liao DJ: Reviewing once more the c-myc and Ras collaboration: Converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle. 10:57–67. 2011. View Article : Google Scholar : PubMed/NCBI
17	Collier TL, Schiller PW and Waterhouse RN: Radiosynthesis and in vivo evaluation of the pseudopeptide delta-opioid antagonist [(125)I] ITIPP(psi). Nucl Med Biol. 28:375–381. 2001. View Article : Google Scholar : PubMed/NCBI
18	Nicoll J, Axiotis CA and Bergasa NV: The delta opioid receptor 1 is expressed by proliferating bile ductules in rats with cholestasis: Implications for the study of liver regeneration and malignant transformation of biliary epithelium. Med Hypotheses. 65:1099–1105. 2005. View Article : Google Scholar : PubMed/NCBI
19	Hannon GJ: RNA interference. Nature. 418:244–251. 2002. View Article : Google Scholar : PubMed/NCBI
20	Ren YJ and Zhang Y: An update on RNA interference-mediated gene silencing in cancer therapy. Expert Opin Biol Ther. 14:1581–1592. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lazarczyk M, Matyja E and Lipkowski AW: A comparative study of morphine stimulation and biphalin inhibition of human glioblastoma T98G cell proliferation in vitro. Peptides. 31:1606–1612. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hatzoglou A, Bakogeorgou E and Castanas E: The antiprolif-erative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol. 296:199–207. 1996. View Article : Google Scholar : PubMed/NCBI
23	Kuniyasu H, Luo Y, Fujii K, Sasahira T, Moriwaka Y, Tatsumoto N, Sasaki T, Yamashita Y and Ohmori H: CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver. Gut. 59:348–356. 2010. View Article : Google Scholar
24	Effendi K, Mori T, Komuta M, Masugi Y, Du W and Sakamoto M: Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression. Cancer Sci. 101:666–672. 2010. View Article : Google Scholar : PubMed/NCBI
25	Fantappiè O, Solazzo M, Lasagna N, Platini F, Tessitore L and Mazzanti R: P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res. 67:4915–4923. 2007. View Article : Google Scholar : PubMed/NCBI
26	Ling X, He Y, Zhang G, Zhou Y and Yan B: Increased P-glycoprotein expression in mitochondria is related to acquired multidrug resistance in human hepatoma cells depleted of mitochondrial DNA. Int J Oncol. 40:109–118. 2012.